| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $52,190,720 | 79 | 100 |
| Harrington Robert Arthur | director | 0 | $0 | 1 | $143,620 | $-143,620 |
| Landry Robert E | director | 0 | $0 | 2 | $146,790 | $-146,790 |
| PARSHALL B LYNNE | director | 0 | $0 | 4 | $1.36M | $-1.36M |
| WIERENGA WENDELL | director | 0 | $0 | 2 | $1.63M | $-1.63M |
| HENDERSON JOHN T | director | 0 | $0 | 2 | $2.08M | $-2.08M |
| Kaye Edward M. MD | director | 0 | $0 | 3 | $2.43M | $-2.43M |
| Malik Fady Ibraham | EVP Research & Development | 0 | $0 | 20 | $5.07M | $-5.07M |
| Lee Sung | EVP, Chief Financial Officer | 0 | $0 | 5 | $5.7M | $-5.7M |
| Callos Andrew | EVP, Chief Commercial Officer | 0 | $0 | 22 | $16.02M | $-16.02M |
| Blum Robert I | President & CEO | 0 | $0 | 18 | $17.62M | $-17.62M |
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in …
Over the last 12 months, insiders at Cytokinetics, Incorporated have bought $0 and sold $52.19M worth of Cytokinetics, Incorporated stock.
On average, over the past 5 years, insiders at Cytokinetics, Incorporated have bought $0 and sold $28.07M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 118,413 shares for transaction amount of $1.13M was made by BVF PARTNERS L P/IL (10 percent owner) on 2019‑12‑11.
| 2026-11-03 | Sale | Malik Fady Ibraham | EVP Research & Development | 3,500 0.0025% | $62.93 | $220,255 | -0.99% | |
| 2026-11-02 | Sale | Blum Robert I | President & CEO | 7,500 0.0057% | $62.81 | $471,075 | +0.45% | |
| 2026-10-20 | Sale | Malik Fady Ibraham | EVP Research & Development | 3,500 0.0025% | $64.01 | $224,035 | -2.78% | |
| 2026-10-12 | Sale | Blum Robert I | President & CEO | 7,500 0.0057% | $62.88 | $471,600 | -0.75% | |
| 2026-10-06 | Sale | Malik Fady Ibraham | EVP Research & Development | 3,500 0.0028% | $61.38 | $214,830 | +1.58% | |
| 2026-09-28 | Sale | Blum Robert I | President & CEO | 7,500 0.0056% | $65.46 | $490,950 | -5.27% | |
| 2026-09-22 | Sale | Malik Fady Ibraham | EVP Research & Development | 3,500 0.0028% | $68.29 | $239,015 | -7.05% | |
| 2026-09-15 | Sale | Landry Robert E | director | 1,000 0.0008% | $72.13 | $72,130 | -9.12% | |
| 2026-09-15 | Sale | Blum Robert I | President & CEO | 97,926 0.0787% | $69.33 | $6.79M | -9.12% | |
| 2026-09-14 | Sale | Blum Robert I | President & CEO | 7,500 0.0058% | $73.44 | $550,800 | -12.84% | |
| 2026-09-11 | Sale | Landry Robert E | director | 1,000 0.0008% | $74.66 | $74,660 | -14.18% | |
| 2026-09-08 | Sale | Malik Fady Ibraham | EVP Research & Development | 3,500 0.0027% | $75.46 | $264,110 | -15.49% | |
| 2026-09-01 | Sale | PARSHALL B LYNNE | director | 5,000 0.004% | $71.48 | $357,400 | -9.94% | |
| 2026-08-31 | Sale | Blum Robert I | President & CEO | 7,500 0.0056% | $70.24 | $526,800 | -8.81% | |
| 2026-08-31 | Sale | Callos Andrew | EVP, Chief Commercial Officer | 10,000 0.0075% | $70.24 | $702,400 | -8.81% | |
| 2026-08-18 | Sale | Malik Fady Ibraham | EVP Research & Development | 3,500 0.0028% | $75.82 | $265,370 | -13.62% | |
| 2026-08-10 | Sale | Blum Robert I | President & CEO | 7,500 0.0056% | $76.76 | $575,700 | -13.72% | |
| 2026-07-30 | Sale | Callos Andrew | EVP, Chief Commercial Officer | 14,000 0.0112% | $79.88 | $1.12M | -13.81% | |
| 2026-07-27 | Sale | Blum Robert I | President & CEO | 7,500 0.006% | $80.87 | $606,525 | -13.60% | |
| 2026-07-21 | Sale | Malik Fady Ibraham | EVP Research & Development | 3,500 0.0028% | $80.59 | $282,065 | -12.27% |
| HENDERSON JOHN T | director | 75237 0.0541% | $4.69M | 1 | 14 | +75.35% |
| SCHMERTZLER MICHAEL | director | 4340923 3.1224% | $270.48M | 1 | 8 | +68.65% |
| Eastern Capital LTD | 10 percent owner | 2883845 2.0744% | $179.69M | 1 | 0 | |
| DOW STEPHEN M | director | 1421052 1.0222% | $88.55M | 9 | 1 | <0.0001% |
| BVF PARTNERS L P/IL | 463244 0.3332% | $28.86M | 2 | 2 | +74.11% | |
| GAGE L PATRICK | director | 28932 0.0208% | $1.8M | 4 | 8 | +19.97% |
$159,914,414 | 243 | 18.52% | $8.86B | |
$67,892,722 | 138 | 28.28% | $6.25B | |
$273,531,368 | 93 | 38.24% | $9.16B | |
$2,765,836 | 72 | 20.00% | $10.77B | |
$613,304,943 | 46 | 11.85% | $6.22B |
| Increased Positions | 251 | +59.34% | 11M | +7.41% |
| Decreased Positions | 186 | -43.97% | 14M | -9.82% |
| New Positions | 106 | New | 3M | New |
| Sold Out Positions | 47 | Sold Out | 3M | Sold Out |
| Total Postitions | 488 | +15.37% | 139M | -2.41% |
| T. Rowe Price Investment Management, Inc. | $1.18M | 15.64% | 19.08M | +1M | +8.4% | 2025-09-30 |
| Blackrock, Inc. | $958,404.00 | 12.73% | 15.53M | -152,120 | -0.97% | 2025-09-30 |
| Fmr Llc | $808,147.00 | 10.73% | 13.09M | +2M | +16.19% | 2025-09-30 |
| Vanguard Group Inc | $731,920.00 | 9.72% | 11.86M | -127,043 | -1.06% | 2025-09-30 |
| Wellington Management Group Llp | $457,330.00 | 6.07% | 7.41M | -419,118 | -5.35% | 2025-09-30 |
| State Street Corp | $346,758.00 | 4.6% | 5.62M | -755,419 | -11.85% | 2025-09-30 |
| Deep Track Capital, Lp | $265,439.00 | 3.53% | 4.3M | +650,000 | +17.81% | 2025-09-30 |
| Bank Of America Corp /De/ | $189,005.00 | 2.51% | 3.06M | +416,228 | +15.73% | 2025-09-30 |
| Geode Capital Management, Llc | $187,672.00 | 2.49% | 3.04M | +45,757 | +1.53% | 2025-09-30 |
| Polar Capital Holdings Plc | $171,790.00 | 2.28% | 2.78M | -15,471 | -0.55% | 2025-09-30 |